Daily Stock Analysis, RARX, Ra Pharmaceuticals Inc, priceseries

Ra Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
47.99
Close
47.99
High
47.99
Low
47.99
Previous Close
47.99
Daily Price Gain
-0.00
YTD High
48.02
YTD High Date
Mar 31, 2020
YTD Low
40.30
YTD Low Date
Mar 18, 2020
YTD Price Change
0.96
YTD Gain
2.04%
52 Week High
48.02
52 Week High Date
Mar 31, 2020
52 Week Low
40.30
52 Week Low Date
Mar 18, 2020
52 Week Price Change
1.24
52 Week Gain
2.65%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 12. 2017
23.07
May 26. 2017
24.54
10 Trading Days
6.39%
Link
LONG
Oct 12. 2017
14.63
Oct 19. 2017
15.41
5 Trading Days
5.32%
Link
LONG
Apr 12. 2018
5.63
Apr 24. 2018
5.99
8 Trading Days
6.42%
Link
LONG
Jun 6. 2018
7.19
Jun 22. 2018
8.66
12 Trading Days
20.43%
Link
LONG
Aug 30. 2018
11.23
Oct 4. 2018
16.38
24 Trading Days
45.82%
Link
LONG
Nov 15. 2018
14.67
Nov 20. 2018
15.73
3 Trading Days
7.26%
Link
LONG
Mar 7. 2019
21.92
Mar 20. 2019
25.49
9 Trading Days
16.30%
Link
LONG
Jun 17. 2019
22.74
Jul 23. 2019
33.62
25 Trading Days
47.83%
Link
Company Information
Stock Symbol
RARX
Exchange
NasdaqGM
Company URL
http://www.rapharma.com
Company Phone
(617) 401-4060
CEO
Doug Treco
Headquarters
Massachusetts
Business Address
87 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA 02140
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001481512
About

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It provides pharmaceutical products for treatment of diseases of complement dysregulation. It utilizes small molecules and peptide to address pathological targets in the complement cascade. It develops a portfolio of drugs and partnerships focused on intracellular protein-protein interactions and other innovative approaches for addressing unmet medical needs. The company was founded by Doug A. Treco and James W. Broderick in 2008 and is headquartered in Cambridge, MA.

Description

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.